RESEARCH PAPER
Non-adherence to antiretroviral treatment and associated factors among people living with HIV in Iran: a retrospective cohort study
1
Department of Biostatistics and Epidemiology, Faculty of Health and Nutrition, Bushehr University of Medical Sciences, Bushehr, Iran
2
Student Research Committee, Shiraz University of Medical Sciences, Shiraz , Iran
3
Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
4
Department of Epidemiology, Shiraz University of Medical Sciences, Shiraz, Iran
5
HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Submission date: 2021-07-04
Final revision date: 2021-07-24
Acceptance date: 2021-08-01
Publication date: 2023-04-03
HIV & AIDS Review 2023;22(2):131-137
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Although combination of antiretroviral therapy (cART) has been successful in improving health outcomes of people living with HIV (PLWH), optimal treatment adherence is required to maintain the benefits. This study aimed to determine factors associated with treatment non-adherence among PLWH in Iran.
Material and methods:
In this cohort study, we included 988 PLWH (1997-2017) living in Southern Iran, Fars Province. Required demographic and clinical data was collected from patients’ files. Non-adherence was defined by a physician of the center as skipping a visit or less than 90% intake of prescribed medicines (antiretroviral drugs) in the month preceding to the date of data collection.
Results:
Of the 988 participants, 70.54% were males. Mean (SD) age of the participants was 35.80 (SD = 8.58) years and treatment non-adherence was found in 17.81% of patients (n = 176). Multiple regression model showed that injection drug use (IDU) (AOR = 2.53, 95% CI: 1.11-5.74%), and history of incarceration (AOR = 4.20, 95% CI: 1.65-10.66%) increased the likelihood of treatment non-adherence, while taking medications for pneumocystis pneumonia (AOR = 0.34, 95% CI: 0.22-0.52%), duration of being under ART (AOR = 0.13, 95% CI: 0.08-0.21%) for 1-5 years, and (AOR = 0.06, 95% CI: 0.02-0.16%) for more than 5 years, decreased the likelihood of treatment non-adherence.
Conclusions:
These findings show that one in five PLWH did not adhere to cART. On the other hand, the likelihood of non-adherence was directly associated with IDU and incarceration history. Based on the results, tailored programs should be developed to improve adherence among individuals with a history of IDU or incarceration.
Although combination of antiretroviral therapy (cART) has been successful in improving health outcomes of people living with HIV (PLWH), optimal treatment adherence is required to maintain the benefits. This study aimed to determine factors associated with treatment non-adherence among PLWH in Iran.
Material and methods:
In this cohort study, we included 988 PLWH (1997-2017) living in Southern Iran, Fars Province. Required demographic and clinical data was collected from patients’ files. Non-adherence was defined by a physician of the center as skipping a visit or less than 90% intake of prescribed medicines (antiretroviral drugs) in the month preceding to the date of data collection.
Results:
Of the 988 participants, 70.54% were males. Mean (SD) age of the participants was 35.80 (SD = 8.58) years and treatment non-adherence was found in 17.81% of patients (n = 176). Multiple regression model showed that injection drug use (IDU) (AOR = 2.53, 95% CI: 1.11-5.74%), and history of incarceration (AOR = 4.20, 95% CI: 1.65-10.66%) increased the likelihood of treatment non-adherence, while taking medications for pneumocystis pneumonia (AOR = 0.34, 95% CI: 0.22-0.52%), duration of being under ART (AOR = 0.13, 95% CI: 0.08-0.21%) for 1-5 years, and (AOR = 0.06, 95% CI: 0.02-0.16%) for more than 5 years, decreased the likelihood of treatment non-adherence.
Conclusions:
These findings show that one in five PLWH did not adhere to cART. On the other hand, the likelihood of non-adherence was directly associated with IDU and incarceration history. Based on the results, tailored programs should be developed to improve adherence among individuals with a history of IDU or incarceration.
REFERENCES (42)
1.
Mehri A, Alimohamadi Y, Mohammadi M, Sepandi M, Khodamoradi F, Eesmaeilzadeh F. Trend of HIV and tuberculosis co-epidemics in different regions of World Health Organization during 2003-2017. HIV AIDS Rev 2020; 19: 167-171.
3.
Damtie Y, Tadese F. Antiretroviral therapy adherence among patients enrolled after the initiation of the Universal Test and Treat strategy in Dessie town: a cross-sectional study. Int J STD AIDS 2020; 31: 886-893.
4.
Dzansi G, Tornu E, Chipps J. Promoters and inhibitors of treatment adherence among HIV/AIDS patients receiving antiretroviral therapy in Ghana: narratives from an underserved population. PLoS One 2020; 15: e0230159.
5.
Leyva-Moral JM, Loayza-Enriquez BK, Palmieri PA, et al. Adherence to antiretroviral therapy and the associated factors among people living with HIV/AIDS in Northern Peru: a cross-sectional study. AIDS Res Ther 2019; 16: 22. doi: 10.1186/s12981-019-0238-y.
6.
Abadiga M, Hasen T, Mosisa G, Abdisa E. Adherence to antiretroviral therapy and associated factors among Human immunodeficiency virus positive patients accessing treatment at Nekemte referral hospital, west Ethiopia, 2019. PLoS One 2020; 15: e0232703.
7.
Chakraborty A, Hershow RC, Qato DM, Stayner L, Dworkin MS. Adherence to antiretroviral therapy among HIV patients in India: a systematic review and meta-analysis. AIDS Behav 2020; 24: 2130-2148.
8.
Belayihun B, Negus R. Antiretroviral treatment adherence rate and associated factors among people living with HIV in Dubti Hospital, Afar Regional State, East Ethiopia. Int Sch Res Notices 2015; 2015: 187360. doi: 10.1155/2015/187360.
9.
Hardon A, Davey S, Gerrits T, et al. From access to adherence: the challenges of antiretroviral treatment: studies from Botswana, Tanzania and Uganda 2006. World Health Organization; 2006.
10.
UNAIDS. HIV/AIDS estimates in the Islamic Republic of Iran in 2018 2019. Available from: https://www.unaids.org/en/regi....
11.
Kalan ME, Han J, Taleb ZB, et al. Quality of life and stigma among people living with HIV/AIDS in Iran. HIV/AIDS (Auckland) 2019; 11: 287-298.
12.
Doosti-Irani A, Holakouie-Naieni K. Determination the research priorities in the field of HIV/AIDS in Iran: a systematic review article. Iran J Public Health 2016; 45: 1149-1158.
13.
Hooshyar SH, Ranjbar E, Sharifi H, et al. Evaluating the HIV continuum of care and treatment in a low prevalence city in Iran: Kerman HIV-friendly city initiative. East African Journal of Applied Health Monitoring and Evaluation; 2018.
14.
Morowatisharifabad MA, Movahed E, Farokhzadian J, et al. Antiretroviral therapy adherence and its determinant factors among people living with HIV/AIDS: a case study in Iran. BMC Res Notes 2019; 12: 162. doi: 10.1186/s13104-019-4204-5.
15.
Ghalehkhani N, Farhoudi B, Gouya MM, et al. The HIV treatment cascade in people living with HIV in Iran in 2014: mixed-method study to measure losses and reasons. Int J STD AIDS 2019; 30: 1257-1264.
16.
Ali B, Nisar N, Nawab F. Adherence to antiretroviral therapy in HIV-positive, male intravenous drug users in Pakistan. East Mediterr Health J 2018; 24: 237-242.
17.
Banagi Yathiraj A, Unnikrishnan B, Ramapuram JT, et al. Factors influencing adherence to antiretroviral therapy among people living with HIV in Coastal South India. J Int Assoc Provid AIDS Care 2016; 15: 529-533.
18.
Wakibi SN, W Ng’ang’a Z, Mbugua GG. Factors associated with non-adherence to highly active antiretroviral therapy in Nairobi, Kenya. AIDS Res Ther 2011; 8: 43. doi: 10.1186/1742-6405-8-43.
19.
Suryana K, Suharsono H, Antara I. Factors Associated with adherence to anti-retroviral therapy among people living with HIV/AIDS at Wangaya Hospital In Denpasar, Bali, Indonesia: a cross-sectional study HIV/AIDS. HIV AIDS (Auckl) 2019; 11: 307-312.
20.
Xuan Tran B, Thanh Nguyen L, Hoang Nguyen N, Van Hoang Q. Determinants of antiretroviral treatment adherence among HIV/AIDS patients: a multisite study. Glob Health Action 2013; 6: 19570. doi: 10.3402/gha.v6i0.19570.
21.
Jima F, Tatiparthi R. Prevalence of nonadherence and its associated factors affecting on HIV adults follow-up at antiretroviral therapy clinic in Batu Hospital, Eastern Ethiopia. Indian J Sex Transm Dis AIDS 2018; 39: 91-97.
22.
Ceylan E, Koç A, İnkaya AÇ, Ünal S. Determination of medication adherence and related factors among people living with HIV/AIDS in a Turkish university hospital. Turk J Med Sci 2019; 49: 198-205.
23.
Jones HS, Floyd S, Stangl A, et al. Association between HIV stigma and antiretroviral therapy adherence among adults living with HIV: baseline findings from the HPTN 071 (PopART) trial in Zambia and South Africa. Trop Med Int Health 2020; 25: 1246-1260.
24.
Iroh PA, Mayo H, Nijhawan AE. The HIV care cascade before, during, and after incarceration: a systematic review and data synthesis. Am J Public Health 2015; 105: e5-e16. doi: 10.2105/AJPH.2015.302635.
25.
Rowell-Cunsolo TL, Hong HK, Mkuu R, Britton A. Improving medication adherence among drug-using HIV-infected formerly incarcerated individuals: a pilot test of two interventions. J Correct Health Care 2020; 26: 42-54.
26.
Baillargeon J, Giordano TP, Rich JD, et al. Accessing antiretroviral therapy following release from prison. JAMA 2009; 301: 848-857.
27.
Rozanova J, Brown SE, Bhushan A, Marcus R, Altice FL. Effect of social relationships on antiretroviral medication adherence for people living with HIV and substance use disorders and transitioning from prison. Health Justice 2015; 3: 18. doi: 10.1186/s40352-015-0030-6.
28.
Vlahov D, Celentano DD. Access to highly active antiretroviral therapy for injection drug users: adherence, resistance, and death. Cad Saude Publica 2006; 22: 705-718.
29.
Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction 2008; 103: 1242-1257.
30.
Li L, Lin C, Lee SJ, Tuan LA, Feng N, Tuan NA. Antiretroviral therapy adherence and self-efficacy among people living with HIV and a history of drug use in Vietnam. Int J STD AIDS 2017; 28: 1247-1254.
31.
Werb D, Milloy MJ, Kerr T, Zhang R, Montaner J, Wood E. Injection drug use and HIV antiretroviral therapy discontinuation in a Canadian setting. AIDS Behav 2013; 17: 68-73.
32.
Tasaka S. Pneumocystis pneumonia in human immunodeficiency virus-infected adults and adolescents: current concepts and future directions. Clin Med Insights Circ Respir Pulm Med 2015; 9 (Suppl 1): 19-28.
33.
Dworkin MS, Hanson DL, Kaplan JE, Jones JL, Ward JW. Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds. J Infect Dis 2000; 182: 611-615.
34.
Lim PL, Zhou J, Ditangco RA, et al. Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database. J Int AIDS Soc 2012; 15: 1. doi: 10.1186/1758-2652-15-1.
35.
Qin Y, Lu Y, Zhou Y, et al. Timing of antiretroviral therapy for HIV-infected patients with moderate to severe Pneumocystis pneumonia: study protocol for a multi-centre prospective randomised controlled trial. Trials 2020; 21: 551. doi: 10.1186/s13063-020-04450-8.
36.
Mitiku H, Abdosh T, Teklemariam Z. Factors affecting adherence to antiretroviral treatment in harari national regional state, Eastern Ethiopia. ISRN AIDS 2013; 2013: 960954. doi: 10.1155/2013/960954.
37.
Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296: 679-690.
38.
Gupta M, Das SC. Determinants contributing for poor adherence to antiretroviral therapy: a hospital record-based study in Balasore, Odisha. J Fam Med Primary Care 2019; 8: 1720-1724.
39.
Hasabi IS, Shivashankarappa AB, Kachapur C, Kaulgud RS. A study of compliance to antiretroviral therapy among HIV infected patients at a tertiary care Hospital in North Karnataka. J Clin Diagn Res 2016; 10: OC27-OC31.
40.
Dutra BS, Lédo AP, Lins-Kusterer L, Luz E, Prieto IR, Brites C. Changes health-related quality of life in HIV-infected patients following initiation of antiretroviral therapy: a longitudinal study. Braz J Infect Dis 2019; 23: 211-217.
41.
Kazerooni P, Fararouei M, Nejat M, Akbarpoor M, Sedaghat Z. Under-ascertainment, under-reporting and timeliness of Iranian communicable disease surveillance system for zoonotic diseases. Public Health 2018; 154: 130-135.
42.
Zarei N, Joulaei H, Darabi E, Fararouei M. Stigmatized attitude of healthcare providers: a barrier for delivering health services to HIV positive patients. Int J Commun Based Nurs Midwifery 2015; 3: 292-300.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
